Form 4: United Therapeutics COO Sells Shares Under 10b5-1 Plan

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned option exercises and subsequent sales of company common stock totaling 22,500 shares.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), reported transactions on December 22, 2025.
• The transactions involved the exercise of stock options and the subsequent sale of the resulting common stock.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan established on June 3, 2025.
• A total of 14,625 stock options were exercised at a price of $117.76 per share, held in a trust where Benkowitz is a beneficiary.
• An additional 7,875 stock options (6,190 + 1,685) were exercised at a price of $146.03 per share, held in a trust for family members.
• All 22,500 shares acquired from these option exercises were sold on the same day, December 22, 2025.
• Sale prices for the shares ranged from approximately $511.13 to $519.02 per share, with weighted average prices reported for multiple trades.
• Following these transactions, the beneficial ownership of common stock from these specific option exercises in both trusts is 0.00 shares.
• Benkowitz retains beneficial ownership of 126,375 stock options in the trust where he is a beneficiary and 68,065 stock options in the trust for family members.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be a concern, these transactions were pre-planned under a 10b5-1 plan, mitigating the implication of a negative outlook. The executive is monetizing vested compensation at favorable prices, which is a positive for the individual.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured approach to managing equity compensation rather than a reaction to new information.
• The significant difference between the option exercise prices ($117.76 and $146.03) and the sale prices (ranging from $511.13 to $519.02) indicates substantial personal financial gain for the reporting person.

Negatives

• The sale of 22,500 shares by a high-ranking executive, even if pre-planned, represents a reduction in insider ownership, which can sometimes be perceived negatively by the market.

Risks

• While the sales were pre-planned, significant insider selling could potentially lead to negative market sentiment or speculation, impacting the company's stock price.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports routine insider transactions and does not provide information directly related to broader industry trends or competitive landscape. It reflects an executive's personal financial planning within the context of their compensation structure.

Corporate Governance

Related Party Transactions

• The transactions involved shares held in two trusts: one where the reporting person is a beneficiary and co-trustee with their spouse, and another where the reporting person's family members are beneficiaries and the reporting person has sole investment and voting power. These are considered related party transactions.

Stakeholder Impact

• Shareholders: May observe a reduction in direct insider ownership, though the pre-planned nature of the sales under a 10b5-1 plan typically lessens concerns about management's confidence in the company's future.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 reports routine, pre-planned insider transactions (option exercises and sales) by a key executive. Such transactions, especially when executed under a Rule 10b5-1 plan, are generally not indicative of a change in the company's fundamental outlook or a signal for immediate investment action. The executive is monetizing vested compensation, which is a common practice. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to warrant a change in investment thesis.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, Rule 10b5-1 Plan, Executive Compensation, Share Sale, Michael Benkowitz